Last updated: 11/07/2018 18:09:32
A Phase I Trial to Evaluate the Safety and Pharmacokinetics of 141W94 (Protease Inhibitor).
Clinicaltrials.gov ID
Not applicable
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Study complete
Study complete
Trial overview
Official title: A Phase I Trial to Evaluate the Safety and Pharmacokinetics of 141W94 (Protease Inhibitor).
Trial description: A Phase I Trial to Evaluate the Safety and Pharmacokinetics of 141W94 (Protease Inhibitor).
Primary purpose:
Not applicable
Trial design:
Not applicable
Masking:
Not applicable
Allocation:
Not applicable
Primary outcomes:
Not applicable
Secondary outcomes:
Not applicable
Interventions:
Not applicable
Enrollment:
Not applicable
Primary completion date:
Not applicable
Observational study model:
Not applicable
Time perspective:
Not applicable
Clinical publications:
Sadler BM, Elkins M, Hanson C, Rooney J, Millard J, Blum MR, Painter G. The safety and pharmacokinetics of 141W94: an HIV Protease Inhibitor. Fifth European Conference on Clinical Aspects and Treatment of HIV-Infection, 26-29 September 1995, Copenhagen, Denmark, Abstract No 564.
Sadler BM, Hanson CD, Chittick GE, Symonds WT, and Roskell NS, Safety and Pharmacokinetics of Amprenavir (141W94), a Human Immunodeficiency Virus (HIV) Type 1 Protease Inhibitor, following Oral Administration of Single Doses to HIV-Infected Adults. Antimicrob. Agents Chemother. 1999 43: 1686-1692..
Medical condition
Infection, Human Immunodeficiency Virus
Product
amprenavir
Collaborators
Not applicable
Study date(s)
N/A to Invalid Date
Type
Not applicable
Phase
1
Participation criteria
Sex
Not applicable
Age
Not applicable
Accepts healthy volunteers
Not applicable
Inclusion and exclusion criteria
Trial location(s)
This study does not involve prospective enrollment of participants.
Study documents
Scientific result summary
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Not applicable
Recruitment status
Study complete
Actual primary completion date
Not applicable
Actual study completion date
Not applicable
Plain language summaries
Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.
Additional information about the trial
Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website